艾立布林治疗多线化疗失败晚期软组织肉瘤患者的疗效和安全性  

Efficacy and safety of eribulin in the treatment of patients with advanced soft tissue sarcoma after failure of multi-line chemotherapy

作　　者：赵盼 桑蝶 王依盟 李诗语 ZHAO Pan;SANG Die;WANG Yimeng;LI Shiyu(Department of General,Beijing Chaoyang District Sanhuan Cancer Hospital,Beijing 100122,China)

机构地区：[1]北京市朝阳区三环肿瘤医院综合科,北京100122

出　　处：《癌症进展》2022年第5期457-460,共4页Oncology Progress

摘　　要：目的 探讨艾立布林治疗多线化疗失败晚期软组织肉瘤患者的疗效和安全性。方法 选取7例一线以上化疗失败晚期软组织肉瘤患者,均给予艾立布林注射治疗。采用实体瘤疗效评价标准1.1评价临床疗效,常见不良事件评价标准4.0评估不良反应发生情况。结果 7例一线以上化疗失败晚期软组织肉瘤患者总共完成26个周期的治疗,每例患者治疗2~8个周期,中位治疗2个周期。给予艾立布林治疗期间疗效评价为部分缓解(PR)1例,疾病稳定(SD)2例,疾病进展(PD)4例,客观有效率为14.29%(1/7),临床获益率为42.86%(3/7)。截至2021年10月3日,生存2例,因病情进展死亡5例,所有患者均获得随访,随访时间8~14个月,中位无进展生存期(PFS)为2个月,中位总生存期(OS)为12个月。出现的主要不良反应为乏力4例、白细胞减少4例、周围神经损伤3例、胃肠道反应2例、贫血2例、肝功能损伤1例,且均为可耐受的1~2级不良反应,经对症处理后未影响继续治疗。结论 艾立布林治疗多线化疗失败晚期软组织肉瘤有一定疗效,其总体不良反应轻微,安全性好。Objective To investigate the efficacy and safety of eribulin in the treatment of patients with advanced soft tissue sarcoma who failed multiple lines of chemotherapy. Method Seven patients with advanced soft tissue sarcoma who failed first-line chemotherapy were selected and given eribulin injection. The clinical efficacy was evaluated by the response evaluation criteria in solid tumor 1.1, and the common terminology criteria adverse event 4.0 was used to evaluate the occurrence of adverse reactions. Result Seven patients with advanced soft tissue sarcoma who failed first-line chemotherapy completed a total of 26 cycles of treatment, each patient received 2-8 cycles of treatment, with a median of2 cycles of treatment. During treatment with eribulin, the efficacy evaluation was partial response(PR) in 1 case, stable disease(SD) in 2 cases, and progressive disease(PD) in 4 cases, the objective effective rate was 14.29%(1/7), and the clinical benefit rate was 42.86%(3/7). As of October 3, 2021, 2 patients survived and 5 died due to disease progression,all patients were followed up for 8 to 14 months, and the median progression-free survival(PFS) was 2 months and the median overall survival(OS) was 12 months. The main adverse reactions were fatigue in 4 cases, leukopenia in 4 cases,peripheral nerve injury in 3 cases, gastrointestinal reaction in 2 cases, anemia in 2 cases, and liver function damage in 1case, and all were tolerable grade 1-2 adverse reactions, which did not affect continued treatment after symptomatic treatment. Conclusion Eribulin has a certain curative effect in the treatment of advanced soft tissue sarcoma after failure of multi-line chemotherapy, and its overall adverse reactions are mild and safe.

关 键 词：艾立布林 软组织肉瘤 疗效 不良反应 

分 类 号：R738.6[医药卫生—肿瘤]